New sedation method may reduce breathing risks during heart procedure in elderly

NCT ID NCT07532733

Recruiting now Symptom relief Sponsor: Erasme University Hospital Source: ClinicalTrials.gov ↗

First seen Apr 28, 2026 · Last updated May 31, 2026 · Updated 8 times

Summary

This study tests whether a sedative called dexmedetomidine causes fewer breathing problems than the standard drug combination (propofol and remifentanil) during a minimally invasive heart valve replacement (TAVI) in patients aged 60 and older. Researchers will monitor oxygen levels, breathing rate, and airway function during the procedure. The goal is to find a safer sedation option for elderly patients with multiple health conditions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE AORTIC STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

HUB Erasme
RECRUITING

Brussels, 1070, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

TAVI(TRANSCATHETER AORTIC VALVE IMPLANTATION)

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

SEVERE AORTIC STENOSIS